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摘要
目的:观察玻璃体腔注射 Ranibizumab 联合经瞳孔温热疗法
(TTT)治疗渗出型年龄相关性黄斑变性的临床疗效及安全性。
方法:选取来我院就诊并通过病史、临床症状及眼底血管
照影(FFA/ ICGA)和光学相干断层扫描(OCT)等辅助检
查确诊的渗出型年龄相关性黄斑变性的患者 160 例(160
眼),随机分为联合组和对照组,联合组给予单次行玻璃
体腔注射 Ranibizumab,7d 后行 TTT 治疗,对照组仅行 TTT
治疗,随访 1a,分别于治疗后 1wk;1,6mo;1a,观察患者的
最佳矫正视力、散瞳后眼底的变化及眼底血管照影(FFA/
ICGA)及 OCT 的检查。
结果:观察期末,联合组最佳矫正视力提高34 例(42.50%),
对照组最佳矫正视力提高16 例(20.00%),差异具有统计学
意义(P<0.05)。 治疗后1wk;1,6mo;1a 联合组和对照组的荧
光渗 透 有 效 率 分 别 为 (88. 75%,62. 50%); (91. 25%,
65郾00%);(86.25%,61. 25%);(78. 75%,51. 25%)。 治疗
后 1wk;1,6mo;1a 联合组和对照组黄斑中心厚度分别为:
(347. 43依36. 96) 滋m 和(423. 58依29. 03) 滋m;(287. 78依
34郾 16)滋m 和(387.14依32. 98)滋m;(301.75依37.21)滋m 和
(415. 40依31. 38) 滋m;(326. 17依27. 39) 滋m 和(436. 44依
35郾 49)滋m,两组相比,差异具有统计学意义(P<0. 05)。
结论:玻璃体腔注射 Ranibizumab 联合经瞳孔温热疗法治
疗渗出型年龄相关性黄斑变性,能够使患者的视力得到改
善,病灶渗漏停止或减轻,促进黄斑区出血、水肿及渗出的
吸收,安全、疗效可靠,是一种有效的临床治疗方法。
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Abstract
誗AIM: To observe the efficacy and safety of intravitreal
injection of Ranibizumab with transpupillary
thermotherapy (TTT) in patients with wet age - related
macular degeneration (AMD).
誗 METHODS: Totally 160 wet age - related macular
degeneration patients (160 eyes ) were selected, which
have been diagnosed through history, clinical symptoms
and fundus angiography (FFA/ ICGA) as well as optical
coherence tomography ( OCT ) and other auxiliary
examinations in our hospital. All these patients were
randomly divided into the combined group and the
control group. Combined group was given a single
intravitreal injection Ranibizumab and applied the TTT
treatment after seven days, while the control group only
received the TTT treatment and was being monitored for
1y. The patients爷 best corrected visual acuity, fundus
angiography ( FFA/ ICGA) and OCT examination were
observed after 1wk, 1mo, 6mo and 1y of the treatment,
respectively.
誗RESULTS: By the end of the observation period, there
were 34 cases ( 42. 50%) out of the combined group
whose the best corrected visual acuity have improved,
while 16 cases from the control group (20. 00%) whose
best corrected visual acuity have improved. The
difference between the two groups showed statistically
significance (P<0. 05). More specifically, the fluorescent
penetrant rates are (88.75%, 62.50%), (91.25%, 65.00%),
(86. 25%, 61. 25%), (78. 75%, 51. 25%), respectively, in
both groups after 1wk, 1mo, 6mo and 1y treatment, and
also the corresponding central macular thickness (CMT)
were (347.43依36.96) 滋m and (423.58依29.03) 滋m, (287.78依
34.16) 滋m and (387. 14依32. 98) 滋m, (301. 75依37. 21) 滋m
and (415.40依31.38) 滋m, (326.17依27.39) 滋m and (436.44依
35.49) 滋m. In a nutshell, the difference between the two
groups were statistically significant (P<0.05).
誗 CONCLUSION: Intravitreal injection of Ranibizumab
with TTT treatment applied among patients with wet age-
related macular degeneration ( AMD ) could improve
patients爷 vision, stop or reduce the leakage of the lesion,
as well as promote the absorption of macular
hemorrhage, edema and exudation, which could be
considered as a safe, reliable and effective clinical
treatment.
4 4 7 1
国际眼科杂志摇 2014 年 10 月摇 第 14 卷摇 第 10 期摇 www. ies. net. cn
电话:029鄄82245172摇 摇 82210956摇 摇 摇 电子信箱:IJO.2000@163. com誗 KEYWORDS: transpupillary thermotherapy; wet age -
related macular degeneration; Ranibizumab; intravitreal
injection
DOI:10. 3980/ j. issn. 1672-5123. 2014. 10. 02
Citation: Li J, Sun JH. Ranibizumab with transpupillary
thermotherapy for clinical efficacy in wet age - related macular
degeneration. Guoji Yanke Zazhi(Int Eye Sci) 2014;14(10):1744-1748
INTRODUCTION
A
ge-related macular degeneration (AMD) is one of the
major age - related eye diseases which could cause
blindness of people who are more than 50y old in Western
countries
[1]. In China, with the aging of the population in
recent years, the incidence of AMD is increasing year by
year, and getting more attention by domestic and foreign
research scholars. AMD can be divided into dry and wet
according to the clinical and pathological findings. The dry is
mainly for macular retinal pigment epithelium atrophy and
generally does not cause total blindness in patients, although
the wet is only 10% of the AMD
[2] which often leads to severe
visual loss with the poor prognosis and recurrence rate since
the fiber is always considered as retinal degeneration,
choroidal neovascularization ( CNV) and discoid scarring.
Hence there is no effective method of treatment currently.
Transpupillary thermotherapy (TTT) is a method that utilizes
semiconductor laser, low intensity radiation, and heat
transport through the pupil to the pigment epithelium and
choroid. In this case, it will not cause coagulation of the local
tissue of the blood vessel occlusion
[3,4]. Currently,
Ranibizumab is known as the strongest anti - vascular
endothelial growth factor (VEGF) biologics; because it has a
small molecular weight also can penetrate the retina and
reduce the formation of new blood vessels in a better way.
Therefore, we use intravitreal Ranibizumab with TTT
treatment of wet AMD to study the efficacy of this approach
and its clinical significance
[5, 6].
SUBJECTS AND METHODS
Subjects 摇 Our experiments should comply with the
Declaration of Helsinki, approved with the ethics committee,
and signed the informed consent. Totally 160 wet AMD
patients (160 eyes) of the first affiliated hospital of Liaoning
medical university in ophthalmology clinic were selected, from
March 2012 to October 2013, among 88 male cases and 72
female cases, and the age was from 51 to 79 years old with an
average of 66. 5 years old, as well as the duration was from
6mo to 3y with an average of 1. 6y. These patients were
randomly divided into two groups: the combined group and the
control group, 80 cases in each group (80 eyes). All enrolled
patients met the following conditions: (1) Vision: conscious
patients have varying degrees of vision loss, eyes shadow,
central scotoma, visual distortion and decreased contrast
sensitivity and etc. Best corrected visual acuity is between
0郾 01-0. 4, and early treatment diabetic retionopathy study
(ETDRS) number of letters is in 5-50mo; (2) IOP: in the
normal range; (3) Slit lamp microscope: the anterior segment
examination shows no abnormal; (4) After dilated fundus
examination: eyes with varying degrees of macular edema,
oozing and bleeding; ( 5 ) Fundus angiography ( FFA/
ICGA): lesions visible on the different levels of fluorescein
leakage or bleeding is associated with a fluorescent pigment
epithelium around the block and choroidalneovascularization
( CNV ) strong fluorescence serous detachment zone
performance; (6) Optical coherence tomography ( OCT):
visible lesions unusually high reflective areas and macular
edema, thickening, the central macular thickness (CMT) is
at 279-602 (an average of 412. 68依74. 12) 滋m. All eyes are
excluded from corneal disease, cataract, glaucoma, vitreous
opacities and severe high blood pressure, diabetes, liver and
kidney dysfunction and other factors observations, and without
eye surgery, retinal laser photocoagulation and injection
history of the ball in the past, and etc.
Methods
Intravitreal injection of Ranibizumab 摇 All patients for
admission should take a parallel routine preoperative
examination, be given a detailed account of the surgical
purposes, risks, potential complications, and postoperative
care, sign the informed consent of intravitreal Ranibizumab,
apply eye drops 6 times a day in order to clean the
conjunctival and prevent infection 2d before the injection
application of tobramycin. Intravitreal injection of
Ranibizumab is conducted in strict accordance with the formal
steps in a sterile operating room. Before operating, we used
the proparacaine drops to topical anesthesia on the temporal
distance Angle sclera margin of 3. 5 to 4. 0 mm (the ciliary
body flat) into the needle, and slowly injected 0.5 mg/0.05 mL
Ranibizumab into the vitreous cavity, and then removed the
needle after needle mouth swab pressed 2 - 3min. After
referring to measuring intraocular pressure Tn, binding up
with pad were performed. After seven days, the combined
groupapplied the treatment of TTT
[7-9].
The transpupillary thermotherapy treatment摇 All patients
are informed before passing through TTT for the purpose and
possible risks and complications, and patients need sign the
informed consent. Before conducting treatment on the affected
eye with compound tropicamide eye drops sufficiently dilated,
for surface anesthesia drops proparacaine, the patient's head
is fixed on the slit lamp, the oculer laser mirror is placed in a
90毅 in the affected eye, and with the wavelength of 810 nm
joint near infrared laser light fiber in the lesion site. In the
beginning, light control is between 60-120s, energy control
is in 100-300 mW, spot diameter is between 1. 2-3. 0 mm,
until a gray mild or no damage as a benchmark appears. With
the change of the colors, the energy control should also be
changed accordingly, due to the standardization of energy
problem, reactions to TTT individual difference is big, this is
all done by an experienced doctor whose treatment operation to
ensure that all lesion site will have the corresponding
change
[10,11].
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Group
Before therapy
average BCVA
After therapy
One week One month Six months One year
Combination group 0. 30 86. 25% 90. 00% 88. 75% 83. 75%
Control group 0. 25 73. 75% 67. 50% 63. 75% 47. 50%
摇 摇 摇 摇 摇 摇 摇 摇 摇 摇 摇 摇 摇 摇
P 0. 81 0. 009
a 0. 003
a 0. 006
a 0. 002
a
摇 摇 摇 摇 摇 摇
aStatistically significant (P<0. 05).
摇 摇 摇 摇 摇 摇 Table 2摇 The two groups in fluorescence leakage compare different time periods (Efficiency %)
Group
Before therapy
average leakage
After therapy
One week One month Six months One year
Combination group 2. 0 PD 88. 75% 91. 25% 86. 25% 78. 75%
Control group 2. 5 PD 62. 50% 65. 00% 61. 25% 51. 25%
摇 摇 摇 摇 摇 摇 摇 摇 摇 摇 摇 摇 摇 摇
P 0. 79 0. 004
a 0. 003
a 0. 005
a 0. 006
a
摇 摇 摇 摇 摇 摇
aStatistically significant(P<0. 05).
Follow-up observations摇 Observe the best corrected visual
acuity and FFA/ ICGA and optical coherence fault scanning
imaging ( OCT) after 1wk, 1mo, 6mo and 1y treatment,
respectively. ( 1 ) Best corrected visual acuity: adopt
international standards of eye examination for eye vision
correction. Visual acuity improved: improved 逸 2; Vision
loss: decreased 逸2;Vision stable: fluctuations within a row;
If the visual acuity is <0.1 then change 0.02 to 1 line. (2)
FFA/ ICGA: assess the treatment effect according to leakage.
Stop leakage: FFA/ ICGA check without leakage; Reduce
leakage: FFA/ ICGA check for leakage area reduced 逸50%;
Increase leakage: FFA/ ICGA check for leakage area
expanded than before the treatment; Continue leakage: FFA/
ICGA check for leakage area decreased 臆50%. (3) OCT:
use Heidelberg SPECTRALIS frequency - domain OCT to
measure the central macular thickness (CMT), and in order
to ensure the accuracy of the experiment, all check of the
patients should be operated by the same technician
[12,13].
Statistical Analysis摇 Statistical analysis is gained by using
SPSS 10. 0. The data is compared between the two groups by
using the t-test, while the count data statistics is gained by
using x
2 test. P < 0. 05 is considered to be statistically
significant.
RESULTS
Best Corrected Visual Acuity 摇 After 1wk therapy: in
combined group, the total effective rate is 86.25% (69/80),
while in control group, the total effective rate is 73. 75%
(59/80); 1mo after therapy: in combined group, the total
effective rate is 90. 00% (72/80), while in control group,
the total effective rate is 67. 50% (54/80 ); 6mo after
therapy: in combined group, the total effective rate is
88郾 75% (71/80), while in control group, the total effective
rate is 63. 75% (51/80); 1y after therapy: in combined
group, the total effective rate is 83. 75% (67/80), while in
control group, the total effective rate is 47. 50% (38/80).
By t-test, there is no statistically significant difference in the
curative effect of two groups before therapy (P=0. 81). The
difference shows statistically significance on different stages of
time after therapy ( P < 0. 05): the combined group has
improved and stabilized the vision more effectively, and
reduced edema and bleeding dramatically. The results are
shown in Table 1.
Fundus angiography (FFA/ ICGA) 摇 After 1wk therapy:
in combined group, the effective rate on leakage improving is
88.75% (71/80), while in control group, the effective rate
on leakage improving is 62. 50% ( 50/80 ); 1mo after
therapy: in combined group, the effective rate on leakage
improving is 91.25% (73/80), while in control group, the
effective rate on leakage improving is 65. 00% (52/80); 6mo
after therapy: in combined group, the effective rate on
leakage improving is 86. 25% (69/80), while in control
group, the effective rate on leakage improving is 61. 25%
(49/80); 1y after therapy: in combined group, the effective
rate on leakage improving is 78. 75% (63/80), while in
control group, the effective rate on leakage improving is
51郾 25% (41/80).
By t-test, there is no statistically significant difference in the
curative effect of two groups before therapy (P=0. 79). The
difference between the two groups shows statistically
significance in different time periods in terms of improving
leakage after therapy (P<0. 05). The results are shown in
Table 2. The leakage stopped and leakage reduced in
combined group are better than that of in the control group.
The leakage of the eyes is reduced significantly after combined
therapy.
Optical coherence tomography (OCT) 摇 Before therapy,
CMT of the combined group and the control group are
(468郾 72依46. 34)滋m and (456. 59依38. 53)滋m respectively,
there is no statistical significant difference in the two groups
(P = 0. 74). After 1wk, 1mo, 6mo and 1y treatment, the
CMT are (347.43依36. 96) 滋m and (423. 58依29. 03) 滋m,
(287. 78依34. 16) 滋m and (387. 14依32. 98) 滋m, (301.75依
37.21) 滋m and (415.40依31.38) 滋m, (326.17依27. 39) 滋m
and (436. 44 依35. 49) 滋m respectively, compared between
the two groups, and the differences are statistically significant
(P=0. 001, 0.005, 0. 003, 0.007). The results have shown
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(CMT/ 滋m)
Group
Before therapy
average CMT
After therapy
One week One month Six months One year
Combination group 468. 72依 46. 34 347. 43依36. 96 287. 78依34. 16 301. 75依37. 21 326. 17依27. 39
Control group 456. 59依38. 53 423. 58依29. 03 387. 14依32. 98 415. 40依31. 38 436. 44依35. 49
P 0. 74 0. 001
a 0. 005
a 0. 005
a 0. 007
a
摇 摇 摇 摇 摇 摇
aStatistically significant (P<0. 05).
in Table 3. By the end of the therapy, the combined group is
more effective on improving the patients蒺 condition, and
macular edema is significantly reduced compared with the
control group.
Intraocular Pressure 摇 Among all the cases in this
experiment, no case gets higher intraocular pressure, and
intraocular pressure of patients with pre- therapy and post-
therapy are within the normal range.
Adverse Reactions 摇 There is 1 case occurred in patients
suffering from mild pain in the eye 1d after the intravitreal
injection of Ranibizumab, and accompanied by blurred
vision. After checking, the intraocular pressure is in the
normal range, but sight has been dropped 1 line.
Psychological comfort and adequate rest should be given in
1d. In the following-up observation period, endophthalmitis,
cataract, glaucoma and other complications did not occur.
Relapse摇 In the following-up period, there is 1 patient in the
combined group had vision loss in 1mo. There are 2 cases had
blurred vision in 6mo, and the leakage occurred after
implementing fundus angiography. After intravitreal injection
once, sight has improved >2 rows after 1wk.
DISCUSSION
Wet AMD often occurred among people aged over 50 and is
different from dry AMD which has a slowly progressive vision
loss. Patients with wet AMD have vision loss more rapidly,
and vision is often decreased significantly in a short time.
Therefore, wet AMD is the main type of causing
blindness
[14,15]. Principles of dealing with wet AMD is taking
the treatment of CNV early and avoiding lesions expanded.
The ultimate goal of the treatment for exudative AMD is to
close CNV. Therefore any method that can make the CNV
eliminate or shrink can be applied by stopping bleeding,
oozing and the formation of scar machine can preserve the
existing visual function. Current methods of treatment for wet
AMD are laser photocoagulation, macular CNV removal,
macular translocation surgery, thermotherapy, photodynamic
therapy and anti-angiogenesis drug treatment. In this case,
patients could have different choices according to their specific
circumstances. Due to the poor prognosis of wet AMD, there
is no uniform cognition of various treatment methods, hence
the treatment of exudative AMD is still one of the problems
that researchers from ophthalmology are eager to solve
[16, 17].
TTT is a promising treatment recently. With the advantages of
safe, painless, and low cost, the new method of treatment can
be accepted by the majority of patients. The principle of TTT
treatment is by using a semiconductor 810 nm wavelength
infrared laser on the lesion application which can increase the
temperature of the irradiated area by 5-10益 and promote the
macular area renewal intravascular thrombosis and occlusion
which will close CNV, so as to achieve the goal of treatment of
macular area CNV
[18]. Different from the traditional laser
photocoagulation, TTT causes so little damage on the nearby
tissues due to the moderate temperature. In recent years, anti-
VEGF agents become a new anti - angiogenesis targeted
therapy, and have achieved good results in terms of the
clinical treatment of AMD. At the moment, the only anti-
VEGF drugs approved by the US Food and Drug
Administration (FDA) approval of anti-VEGF drugs to cure
eyes is Ranibizumab which is made of artificial improved rat
polyclonal anti-restructuring over the span of derived VEGF
antibody. The polyclonal antibody can be combined with all
isomer VEGF and become inactivated, so as to inhibit the
formation of choroidal neovascularization. Because the
polyclonal has a smaller molecular weight, it can better
penetrate the retina, increase vitreous body bioavailability up
to 50% -60%, and possess good efficacy and safety, and it
becomes one of the hot topics in recent years
[19].
With the continuous development of medical research,
combined therapy has become an emerging treatment, bring to
the treatment of patients with dawn, but TTT combined
intravitreal Ranibizumab treatment of wet AMD has not been
reported. As TTT and intravitreal Ranibizumab have different
mechanisms, there are limitations when used alone in the
treatment of wet AMD. As we know, when using Ranibizumab
alone, the number of intravitreal injection will increase,
specifically, the average number is about two or three times or
more. So the experiment aims to combine the two treatments
of wet AMD, in order to improve the effectiveness of treatment
and reduce the adverse reactions. In the final observation
period of this experiment, 34 people in combined group whose
best corrected visual acuity are improved, and the total
effective rate is 83. 75% (67/80). In control group, 16
people whose best corrected visual acuity are improved, and
the total effective rate is 47. 50% (38/80). The difference
between the two groups is statistically significant (P<0. 05),
and it shows the combined group yields more effective in
improving and stabilizing vision. After 1wk, 1mo, 6mo and
1y therapy, the fluorescent penetrant improves efficiency and
CMT in the two groups. The differences in terms of leakage
improving and edema reducing are statistically significant (P<
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group are better than that in the control group. After suffering
through the eyes of combined therapy, significantly reduced
leakage, and combined group is more effective on improving
patients爷 conditions, macular edema is also significantly
reduced. Studies have shown that with intravitreal injection of
Ranibizumab, postoperative intraocular pressure is a major
complication, but there is no case of intraocular pressure
happened in this experiment. Intraocular pressure in patients
with pre - therapy and post - therapy are within the normal
range, there is 1 case occurred in patients suffering from mild
pain in the eye 1d after intravitreal injection of Ranibizumab,
and accompanied by blurred vision. But with no special
treatment, the symptoms ease soon, hence intravitreal
injection of Ranibizumab with TTT is safe, reliable, and has
less side effects. In the following-up period, only three cases
out of the combined group of patients in the treatment need
one more intravitreal injection. It shows that intravitreal
injection of Ranibizumab with TTT can significantly reduce the
number of intravitreal injections, and maintain long - term
treatment effect.
In the combined group, we use intravitreal injection of
Ranibizumab with TTTamong patients with wet AMD. The
results have shown a significant effect in terms of the
improvement of visual function, the reduction of injection
frequency, the reduction of macular edema, oozing and
bleeding, and the prevention of recurrence and other
aspects
[20,21]. But the mechanism of combined therapy, and
the number and interval of Ranibizumab injections still
remains to be further investigated.
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